{"id":4456,"date":"2023-10-17T14:11:53","date_gmt":"2023-10-17T04:11:53","guid":{"rendered":"\/eu-uk\/?p=4456"},"modified":"2023-10-17T14:11:53","modified_gmt":"2023-10-17T04:11:53","slug":"quarterly-report-period-to-30-september-2023","status":"publish","type":"post","link":"\/eu-uk\/blog\/2023\/10\/17\/quarterly-report-period-to-30-september-2023\/","title":{"rendered":"Quarterly Report &#8211; Period To 30 September 2023"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Orthocell has today published its Quarterly Report for the period ended 30 September 2023.<\/span><\/p>\n<p><b>Highlights for this Quarter include:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Increased total revenue up 71% from Q1 FY23\u00a0\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Second US distributor now actively marketing and selling Striate+\u2122 as a private labelled product<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Nerve repair study to support US regulatory clearance for Remplir\u2122commenced and on track for completion 1Q CY2024<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Pivotal tendon repair study on track for data read out in 4Q CY2023<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Strong balance sheet with $22.3m cash at bank at the end of the quarter<\/span><\/li>\n<\/ul>\n<p>Orthocell Managing Director, Paul Anderson, said:<\/p>\n<p><span style=\"font-weight: 400;\">\u201cWe are very pleased with the performance of our distribution partners and the continued quarterly increase in product revenue. Successful product launches of Remplir<\/span><span style=\"font-weight: 400;\">\u2122<\/span><span style=\"font-weight: 400;\"> in Australia and Striate+<\/span><span style=\"font-weight: 400;\">\u2122<\/span><span style=\"font-weight: 400;\"> in the USA and Europe by our partners, has seen increases in surgeon engagement and broad uptake of our products, ensuring we are well positioned to continue to gain commercial traction and revenue growth.\u201d<\/span><\/p>\n<p><a href=\"https:\/\/bit.ly\/OCC-Sept-Quarterly\"><b>Click here to read today\u2019s ASX release. <\/b><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell has today published its Quarterly Report for the period ended 30 September 2023.<\/p>\n","protected":false},"author":2,"featured_media":4457,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4456","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video"],"aioseo_notices":[],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=4456"}],"version-history":[{"count":1,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4456\/revisions"}],"predecessor-version":[{"id":4458,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4456\/revisions\/4458"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/4457"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=4456"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=4456"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=4456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}